ALIM Pengajuan SEC - Alimera Sciences, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	5299005C650OO6FJ1R63
CIK	1267602

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Alimera Sciences, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

November 13, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 alim13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri
November 7, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 016259202 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box t
September 26, 2024	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in
September 18, 2024	SC 13D/A	ALIM / Alimera Sciences, Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment SC 13D/A 1 p24-2805sc13da.htm ALIMERA SCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 5)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Titl
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	SC 13D/A	ALIM / Alimera Sciences, Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 5 TO THE SCHEDULE 13D Activist Investment SC 13D/A 1 sc13da51292701109162024.htm AMENDMENT NO. 5 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per sh
September 16, 2024	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissi
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	POS AM	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ALIMERA SCIENCES, INC.   Exhibit 3.1   AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ALIMERA SCIENCES, INC.   FIRST:            The name of the corporation is:   ALIMERA SCIENCES, INC.   SECOND:       The address of its registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware, 19801, County of New Castle. The name of its registered agent at such address is T
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	POS AM	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	S-8 POS	As filed with the Securities and Exchange Commission on September 16, 2024 As filed with the Securities and Exchange Commission on September 16, 2024 Registration No.
September 16, 2024	EX-3.2	AMENDED AND RESTATED BY-LAWS   Exhibit 3.2   AMENDED AND RESTATED BY-LAWS   OF   Alimera Sciences, Inc.   A Delaware Corporation   ARTICLE I   OFFICES   Section 1.      Registered Office. The registered office of the corporation in the State of Delaware shall be located at 1209 Orange Street, in the city of Wilmington, County of New Castle 19801. The name of the corporation's registered agent at such address shall be The Corp
September 11, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 ALIMERA SCIENC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 11, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissi
September 11, 2024	EX-99.1	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger ANI and Alimera Scheduled the Closing for September 16, 2024 Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger ANI and Alimera Scheduled the Closing for September 16, 2024 PRINCETON, N.J. and ATLANTA, September 11, 2024 – ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) (“ANI”) and Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera” or the “Company”) today jointly announced that they have scheduled the closing
September 10, 2024	EX-99.1	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholde Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement Alimera Has Filed Lawsuit in the Delaware Court of Chancery to Compel ANI to Close Merger Transaction and Honor its Contractual Obligations Alimera Shareholders Approved Merger Agreement on September 4, Clearing Last Requirement for Closing ATLANTA, September 10, 2024 – Al
September 10, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 ALIMERA SCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
September 10, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 10, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissi
September 10, 2024	EX-10.3	First Amendment to Employment Agreement Exhibit 10.3 Execution Version First Amendment to Employment Agreement This First Amendment to Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, Georgia (“Alimera” or the “Company”) and Jason
September 10, 2024	EX-10.4	First Amendment to Employment Agreement Exhibit 10.4 Execution Version First Amendment to Employment Agreement This First Amendment to Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, Georgia (“Alimera” or the “Company”) and Todd
September 10, 2024	EX-10.1	First Amendment to the Amended and Restated Employment Agreement Exhibit 10.1 Execution Version First Amendment to the Amended and Restated Employment Agreement This First Amendment to the Amended and Restated Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharet
September 10, 2024	EX-10.2	First Amendment to Employment Agreement Exhibit 10.2 Execution Version First Amendment to Employment Agreement This First Amendment to Employment Agreement (the “Amendment”) is entered into and effective as of September 6, 2024 (the “Effective Date”) by and between Alimera Sciences, Inc., a Delaware corporation having a principal place of business at 6310 Town Square, Suite 400, Alpharetta, Georgia (“Alimera” or the “Company”) and Ellio
August 8, 2024	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 7, 2024	EX-10.6	Letter Agreement, dated as of June 19, 2024, by and between Alimera Sciences, Inc. and SWK Funding LLC. Exhibit 10.6 June 19, 2024 SWK Funding LLC c/o SWK Holdings Corporation 14755 Preston Road, Suite 105 Dallas, Texas 75254 Attention: Joe D. Staggs Re: Alternative Royalty Payment Dear Jody: This letter agreement (this “Letter Agreement”) is entered into as of the date set forth above by and between Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Squ
August 7, 2024	EX-10.7	Manufacturing Services Agreement, dated as of July 17, 2024, by and between Alimera Sciences, Inc. and Alliance Medical Products, Inc. d.b.a. Siegfried Irvine. Exhibit 10.7 Portions of this document have been redacted as marked with [***] Manufacturing Services Agreement Custom Drug Product This Manufacturing Services Agreement (Agreement) is entered into as of July 17, 2024 (the Effective Date) between Alliance Medical Products, Inc., 9342 Jeronimo Rd, Irvine, CA 92618, USA (Siegfried) and Alimera Sciences, Inc., 6310 Town Square, Suite 400, Alpharetta,
August 6, 2024	EX-99.1	Alimera Sciences Reports Second Quarter 2024 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports Second Quarter 2024 Results ● Net Revenue up 54% to $27 Million vs. Q2 2023 ● Global End User Demand Up 6% vs. Q2 2023 ● Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals Inc. ATLANTA, August 6, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mis
August 6, 2024	EX-99.1	Alimera Sciences Reports Second Quarter 2024 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports Second Quarter 2024 Results ● Net Revenue up 54% to $27 Million vs. Q2 2023 ● Global End User Demand Up 6% vs. Q2 2023 ● Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals Inc. ATLANTA, August 6, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mis
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
August 6, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
July 24, 2024	EX-FILING FEES	CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Alimera Sciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Transaction Valuation Exhibit 107 CALCULATION OF FILING FEE TABLES Schedule 14A (Form Type) Alimera Sciences, Inc.
July 24, 2024	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi
July 23, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi
June 24, 2024	EX-10.1	Voting Agreement Exhibit 10.1 Execution Version ** Certain terms of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. The registrant agrees to supplementally furnish an unredacted copy of this exhibit to the SEC upon its request; however, the registrant may request confidential treatm
June 24, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi
June 24, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 ALIMERA SCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi
June 24, 2024	EX-99.1	ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET · Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue · Adds two commercial assets ILUVIEN® and YUTIQ® with significant
June 24, 2024	SC 13D/A	ALIM / Alimera Sciences, Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 4)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da
June 24, 2024	EX-2.1	Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION CONFIDENTIAL AGREEMENT AND PLAN OF MERGER BY AND AMONG: ANI PHARMACEUTICALS, INC. ANIP MERGER SUB INC. and ALIMERA SCIENCES, INC. DATED AS OF JUNE 21, 2024 * The disclosure schedules to and certain provisions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K as they contain information that is both not material and of the type that the
June 24, 2024	EX-99.1	ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET Exhibit 99.1 FOR IMMEDIATE RELEASE ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences Conference call scheduled for today at 8:30 a.m. ET · Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue · Adds two commercial assets ILUVIEN® and YUTIQ® with significant
June 24, 2024	EX-10.1	Voting Agreement Exhibit 10.1 Execution Version ** Certain terms of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as they are both not material and of the type that the registrant treats as private or confidential. The registrant agrees to supplementally furnish an unredacted copy of this exhibit to the SEC upon its request; however, the registrant may request confidential treatm
June 24, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 19, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fi
June 24, 2024	EX-2.1	Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION CONFIDENTIAL AGREEMENT AND PLAN OF MERGER BY AND AMONG: ANI PHARMACEUTICALS, INC. ANIP MERGER SUB INC. and ALIMERA SCIENCES, INC. DATED AS OF JUNE 21, 2024 * The disclosure schedules to and certain provisions of this exhibit have been omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K as they contain information that is both not material and of the type that the
May 16, 2024	SC 13D/A	ALIM / Alimera Sciences, Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel
May 14, 2024	EX-10.4	Seventh Amendment to Loan and Security Agreement dated as of March 6, 2024, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender Exhibit 10.4 Execution Version CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SEVENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of March 6, 2024 (the “Seventh Amendment Effective Da
May 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil
May 14, 2024	EX-99.1	Alimera Sciences Reports First Quarter 2024 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 2024 Results · Net Revenue up 70% to $23 Million vs. Q1 2023 · Global End User Demand Up 23% vs. Q1 2023 · Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invalua
April 29, 2024	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
March 8, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALIMERA SCIENCES, INC.
March 8, 2024	EX-21.1	List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business) Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe Limited Ireland Alimera Sciences Europe Limited
March 8, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34
March 8, 2024	S-8	As filed with the Securities and Exchange Commission on March 8, 2024 As filed with the Securities and Exchange Commission on March 8, 2024 Registration No.
March 8, 2024	EX-97.1	Alimera Sciences, Inc. Clawback Policy ‎ Exhibit 97.1 ALIMERA SCIENCES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE COMPENSATION (Adopted: November 21, 2023) 1. INTRODUCTION Alimera Sciences, Inc. (the “Company”) is adopting this policy (this “Policy”) to provide for the Company’s recovery of certain Incentive Compensation (as defined below) erroneously awarded to Affected Officers (as defined below) under certain circu
March 7, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2024 ALIMERA SCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 6, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi
March 7, 2024	EX-99.1	Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 7, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients,
February 14, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
February 13, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / HBM Healthcare Investments (Cayman) Ltd. - SC 13G/A Passive Investment SC 13G/A 1 tm245871d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Che
February 13, 2024	EX-1	Joint Acquisition Statement Pursuant to Section 240.13d-1(k) EX-1 2 ex-1.htm JOINT ACQUISITION STATEMENT Page 9 of 9 Altium Capital Management, LP SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of
February 13, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / Stonepine Capital Management, LLC Passive Investment SC 13G/A 1 alim13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat
February 13, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / Altium Capital Management LP - AMENDMENT TO FORM SC 13G Passive Investment SC 13G/A 1 altium-sc13ga.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this
February 13, 2024	SC 13G/A	ALIM / Alimera Sciences, Inc. / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 016259202 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to
February 9, 2024	S-8	As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.
February 9, 2024	EX-10.3	Form of Performance Stock Unit Agreement under the 2024 Equity Inducement Plan Exhibit 10.3 Alimera Sciences, Inc. 2024 Equity Inducement Plan Notice of Performance Stock Unit Award Pursuant to the Alimera Sciences, Inc. 2024 Equity Inducement Plan (the “Inducement Plan”), Alimera Sciences, Inc. (the “Company”) hereby grants you the following Performance Stock Units (“PSUs”), each representing the right to receive one share of the Company’s common stock (a “Common Share”),
February 9, 2024	S-8	As filed with the Securities and Exchange Commission on February 9, 2024 As filed with the Securities and Exchange Commission on February 9, 2024 Registration No.
February 9, 2024	EX-10.2	Form of Stock Option Agreement under the 2024 Equity Inducement Plan Exhibit 10.2 Alimera Sciences, Inc. 2024 Equity Inducement Plan Notice of Stock Option Award Pursuant to the Alimera Sciences, Inc. 2024 Equity Inducement Plan (the “Inducement Plan”), Alimera Sciences, Inc. (the “Company”) hereby grants you the following option (the “Option”) to purchase shares of the Company’s common stock (the “Common Shares”), subject to the terms and conditions set forth in
February 9, 2024	EX-10.1	Alimera Sciences, Inc. 2024 Equity Inducement Plan as Adopted on February 8, 2024 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed February 9, 2024, and incorporated herein by reference) Exhibit 10.1 Alimera Sciences, Inc. 2024 Equity Inducement Plan (As Adopted on February 8, 2024) Alimera Sciences, Inc. 2024 Equity Inducement Plan PURPOSE . The purpose of the Plan is to attract, retain, and motivate highly-qualified prospective officers and employees for positions of substantial responsibility by providing an inducement material to their entering into employment with the Compa
February 9, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALIMERA SCIENCES, INC.
February 9, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ‎SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction ‎of incorporation) (Commis
February 9, 2024	EX-10.4	Form of Restricted Stock Unit Agreement under the 2024 Equity Inducement Plan Exhibit 10.4 Alimera Sciences, Inc. 2024 Equity Inducement Plan Notice of Restricted Stock Unit Award Pursuant to the Alimera Sciences, Inc. 2024 Equity Inducement Plan (the “Inducement Plan”), Alimera Sciences, Inc. (the “Company”) hereby grants you the following Restricted Stock Units (“RSUs”), each representing the right to receive one share of the Company’s common stock (a “Common Share”), s
February 9, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALIMERA SCIENCES, INC.
January 4, 2024	EX-10.1	Separation Agreement and General Release, dated January 2, 2024, by and between Alimera Sciences, Inc. and Russell Skibsted EXHIBIT 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is entered into by and between Russell L. Skibsted (“Executive”), for himself and his heirs, executors, administrators, successors, and assigns, and Alimera Sciences, Inc. (“Company”) (Executive and Company each a “Party,” and together, the “Parties”). In consideration of the promises
January 4, 2024	EX-10.2	Employment Agreement, dated as of (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, as filed on January 4, 2024, and incorporated herein by reference) EXHIBIT 10.2 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Elliot Maltz (“Executive”), as of January 2, 2024. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and thr
January 4, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 28, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commissio
January 4, 2024	EX-99.1	Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ATLANTA, January 2, 2024 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better visio
January 4, 2024	EX-10.3	Inducement Stock Option Agreement, dated as of January 2, 2024, by and between Alimera Sciences, Inc. and Elliot Maltz (Non-Plan Inducement Award) EXHIBIT 10.3 ALIMERA SCIENCES, INC. Inducement Stock Option Agreement (Non-Plan Inducement Award) Pursuant to your employment agreement with Alimera Sciences, Inc. (the “Company”), dated December 11, 2023 (the “Employment Agreement”), the Company hereby grants to you (“Executive” or “you”) the following inducement option (the “Option”) to purchase shares of the Company’s common stock (the “Common
December 12, 2023	EX-10.2	Employment Agreement, dated as of December 11, 2023, by and between Alimera Sciences, Inc. and Todd Wood Exhibit 10.2 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Todd Wood (“Executive”), as of December 11, 2023. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and thro
December 12, 2023	EX-10.1	Amended and Restated Employment Agreement, dated as of December 11, 2023, by and between Alimera Sciences, Inc. and Richard S. Eiswirth, Jr. Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Amended and Restated Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Richard S. Eiswirth, Jr. (“Executive”), as of December 11, 2023 (the “Effective Date”). RECITALS: WHEREAS, the Company is engaged in the business of developi
December 12, 2023	EX-10.3	Inducement Stock Option Agreement, dated as of December 11, 2023, by and between Alimera Sciences, Inc. and Todd Wood (Non-Plan Inducement Award) Exhibit 10.3 ALIMERA SCIENCES, INC. Inducement Stock Option Agreement (Non-Plan Inducement Award) Pursuant to your employment agreement with Alimera Sciences, Inc. (the “Company”), dated December 11, 2023 (the “Employment Agreement”), the Company hereby grants to you (“Executive” or “you”) the following inducement option (the “Option”) to purchase shares of the Company’s common stock (the “Commo
December 12, 2023	EX-99.1	Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Exhibit 99.1 Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ATLANTA, December 12, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining
December 12, 2023	8-K	UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ‎SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2023 ALIMERA SCIE UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION ‎Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ‎SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction ‎of incorporation) (Commi
November 8, 2023	EX-99.1	Alimera Appoints Maggie A. Pax to Its Board of Directors FOR IMMEDIATE RELEASE Alimera Appoints Maggie A. Pax to Its Board of Directors ATLANTA (November 8, 2023) – Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Di
November 8, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 o TRANSITION REPO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
October 26, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 26, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
October 26, 2023	EX-99.1	Alimera Sciences Reports Third Quarter 2023 Results FOR IMMEDIATE RELEASE Alimera Sciences Reports Third Quarter 2023 Results · Net Revenue up 72% to $23.
October 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission
October 3, 2023	EX-10.1	Employment Agreement dated as of October 2, 2023 between Alimera Sciences, Inc. and Jason Werner Exhibit 10.1 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Jason Werner (“Executive”), as of October 2, 2023. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and t
October 3, 2023	EX-99.1	Alimera Sciences Appoints Jason Werner as Chief Operating Officer Dr. Philip Ashman Appointed as President of International Operations Exhibit 99.1 Alimera Sciences Appoints Jason Werner as Chief Operating Officer Dr. Philip Ashman Appointed as President of International Operations ATLANTA, October 3, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision
August 23, 2023	EX-1	Joint Acquisition Statement Pursuant to Section 240.13d-1(k) Altium Capital Management, LP SC 13G Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.
August 23, 2023	SC 13G	ALIM / Alimera Sciences Inc. / Altium Capital Management LP - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment SC 13G 1 alimsc13g-082223.htm SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) August 15, 2023 (Date of Even
August 16, 2023	SC 13D/A	ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel
August 15, 2023	EX-3.1	Certificate of Elimination of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on August 15, 2023, and incorporated herein by reference). Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES B CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows: FIRST: By a Certificate of Designation filed with the
August 15, 2023	8-K	Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 15, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
August 14, 2023	SC 13G	ALIM / Alimera Sciences Inc. / LYTTON LAURENCE W Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) August 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
August 11, 2023	EX-10.4	Omnibus Exit Fee Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender Exhibit 10.4 OMNIBUS AMENDMENT TO EXIT FEE AGREEMENTS THIS OMNIBUS AMENDMENT TO EXIT FEE AGREEMENTS (this “Amendment”), dated as of May 18, 2023 (the “Sixth Amendment Effective Date”), is made by and among Alimera Sciences, Inc., a Delaware corporation (the “Borrower”), SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), in its capacity as collateral agent (together with its s
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 o TRANSITION REPORT PU Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 11, 2023	S-8	As filed with the Securities and Exchange Commission on August 11, 2023 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No.
August 11, 2023	EX-10.3	Sixth Amendment to Loan and Security Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp., as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender.* Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of May 17, 2023 (the “Sixth Amendment Effective Date”), b
August 11, 2023	EX-10.5	Joinder and Amendment to Registration Rights Agreement dated as of May 17, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto. Exhibit 10.5 JOINDER AND AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This Joinder and Amendment to Registration Rights Agreement (this “Amendment”) dated as of May 17, 2023 (the “Amendment Effective Date”), between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, amends that certain Registration Rights Agreement (the “R
August 11, 2023	EX-FILING FEES	Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALIMERA SCIENCES, INC.
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
August 10, 2023	SC 13G	ALIM / Alimera Sciences Inc. / BOOTHBAY FUND MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 016259202 (CUSIP Number) August 1, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
August 10, 2023	SC 13G	ALIM / Alimera Sciences Inc. / Stonepine Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 016259202 (CUSIP Number) August 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
August 10, 2023	EX-99.1	Alimera Sciences Reports Second Quarter 2023 Results FOR IMMEDIATE RELEASE Alimera Sciences Reports Second Quarter 2023 Results · Alimera Acquired U.
August 3, 2023	SC 13D/A	ALIM / Alimera Sciences Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 3)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da
August 3, 2023	SC 13D/A	ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel
August 2, 2023	EX-10.1	Alimera Sciences, Inc. 2023 Equity Incentive Plan and forms of award agreements thereunder (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference). EXHIBIT 10.1 Alimera Sciences, Inc. 2023 Equity Incentive Plan (As Adopted on June 15, 2023) Alimera Sciences, Inc. 2023 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Plan was adopted by the Board on June 15, 2023, and will become effective immediately upon its approval by the Company’s stockholders. The purpose of the Plan is to promote the long-term success of the Company and the creation
August 2, 2023	EX-10.2	Chairman Emeritus Agreement, dated as of August 1, 2023 by and between Alimera Sciences, Inc. and C. Daniel Myers (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference). Exhibit 10.2 CHAIRMAN EMERITUS AGREEMENT This Chairman Emeritus Agreement (this “Agreement”) is entered into by and between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and C. Daniel Myers (“Myers”), as of August 1, 2023. RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharmaceuticals in the United States and thro
August 2, 2023	EX-3.1	Certificate of Amendment to Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference). Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing under t
August 2, 2023	EX-4.1	Form of Pre-Funded Warrant (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, as filed on August 2, 2023, and incorporated herein by reference). Exhibit 4.1 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAI
August 2, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
August 1, 2023	424B3	ALIMERA SCIENCES, INC. PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED July 12, 2023 Filed Pursuant to Rule 424(b)(3) Registration No. 333-273090 ALIMERA SCIENCES, INC. PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED July 12, 2023 This Prospectus Supplement No. 1 supplements and amends the prospectus dated July 12, 2023 (the “Prospectus”), covering the offering and sale of up to 49,763,960 shares of common stock, par value $0.01 per share (the “Common Stock”), of Alimera Sciences,
July 12, 2023	424B3	ALIMERA SCIENCES, INC. Up to 49,763,960 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-273090 PROSPECTUS ALIMERA SCIENCES, INC. Up to 49,763,960 Shares of Common Stock This prospectus relates to the resale or other disposition from time to time of up to 49,763,960 shares of common stock, par value $0.01 per share (the “Common Stock”), of Alimera Sciences, Inc., a Delaware corporation, consisting of (i) 45,617,114 shares of
July 10, 2023	CORRESP	Alimera Sciences, Inc. 6310 Town Square, Suite 400 Alpharetta, GA 30005 Alimera Sciences, Inc. 6310 Town Square, Suite 400 Alpharetta, GA 30005 July 10, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attn: Cindy Polynice Re: Alimera Sciences, Inc. Registration Statement on Form S-3 (File No. 333-273090) Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as am
June 30, 2023	S-3	As filed with the Securities and Exchange Commission on June 30, 2023 As filed with the Securities and Exchange Commission on June 30, 2023 Registration No.
June 30, 2023	EX-FILING FEES	Filing Fee Table (filed herewith) Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) ALIMERA SCIENCES, INC.
June 29, 2023	DEF 14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
June 29, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 ALIMERA SCIENCES, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 28, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi
June 15, 2023	PRE 14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒Filed by a Party other than the Registrant ☐ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
June 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 ALIMERA SCIENCES, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil
May 19, 2023	EX-99.4	JOINT FILING AGREEMENT Exhibit 99.4 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Jo
May 19, 2023	SC 13D/A	ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vel
May 19, 2023	EX-99.3	May 17, 2023 Exhibit 99.3 May 17, 2023 Alimera Sciences, Inc. Re: Support Agreement Dear Ladies and Gentlemen: The undersigned understands that Alimera Sciences, Inc., a Delaware corporation (“Company”), and certain investors, including the undersigned (the “Investors”), are entering into a Joinder and Amendment to Securities Purchase Agreement dated as of the date hereof (the “Amendment”), which amends that c
May 18, 2023	EX-10.1	Commercial Supply Agreement, dated May 17, 2023, by and Alimera Sciences, Inc. and EyePoint Pharmaceuticals, Inc. Exhibit 10.1 EXECUTION COPY Confidential CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT (this “Agreement”) is made as of May 17, 2023 (the “Effective Date”), by and between EyePoint Ph
May 18, 2023	EX-10.2	Joinder and Amendment to Securities Purchase Agreement, dated May 17, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto Exhibit 10.2 Execution Version JOINDER AND AMENDMENT TO SECURITIES PURCHASE AGREEMENT This Joinder and Amendment to Securities Purchase Agreement (this “Amendment”) dated as of May 17, 2023 (the “Amendment Effective Date”), between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto, amends that certain Securities Purchase A
May 18, 2023	EX-3.1	Certificate of Amendment to Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on May 18, 2023, and incorporated herein by reference). Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Pursuant to Section 242 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing under t
May 18, 2023	EX-2.1	Product Rights Agreement, dated May 17, 2023, by and Alimera Sciences, Inc. and EyePoint Pharmaceuticals, Inc. Exhibit 2.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc. May 17, 2023 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS.....................
May 18, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission Fil
May 18, 2023	EX-99.1	Alimera Acquires U.S. Commercial Rights to YUTIQ® Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Acquires U.S. Commercial Rights to YUTIQ® · Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 · Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024 · Leverages Alimera’s existing U.S. commercial infrastructure · Industry veteran Jason Werner added to Alimera
May 18, 2023	SC 13D/A	ALIM / Alimera Sciences Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da
May 15, 2023	EX-10.4	Fifth Amendment Exit Fee Agreement dated as of March 24, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender Exhibit 10.4 Fifth Amendment Exit Fee Agreement Reference is made to the Loan and Security Agreement, dated as of December 31, 2019 (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”) by and among SLR Investment Corp., a Maryland corporation (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent (in such capacity, “Agent
May 15, 2023	EX-10.3	Fifth Amendment to Loan and Security Agreement dated as of March 24, 2023, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender* CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
May 15, 2023	EX-99.1	Alimera Sciences Reports First Quarter 2023 Results Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 2023 Results · Consolidated Net Revenue of $13.5 Million Up 14% vs. First Quarter of 2022 · Global End User Demand Up 14% vs. First Quarter of 2022 · Financial Results and Corporate Update Conference Call Cancelled ATLANTA, May 15, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical
May 15, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil
May 15, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 o TRANSITION REPORT P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 1, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One)  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-
April 28, 2023	S-8	As filed with the Securities and Exchange Commission on April 28, 2023 As filed with the Securities and Exchange Commission on April 28, 2023 Registration No.
April 28, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ALIMERA SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate A
April 3, 2023	SC 13G/A	ALIM / Alimera Sciences Inc. / Palo Alto Investors LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 15) Alimera Sciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 016259202 (CUSIP Number) March 24, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
March 31, 2023	EX-21.1	List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business) Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe Limited Ireland Alimera Sciences Europe Limited
March 31, 2023	SC 13D	ALIM / Alimera Sciences Inc. / Velan Capital Investment Management LP - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Adam Morgan Vela
March 31, 2023	EX-99.1	Alimera Sciences Announces 2022 Financial Results and Business Update Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Announces 2022 Financial Results and Business Update · 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 · Global End User Demand Increased 22% over 2021 to 9,266 Units · Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility ATLANTA, March 31, 2023 - Alimera Sciences, Inc. (Nasdaq: ALIM) a global ph
March 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other jurisdiction of incorporation) (Commission F
March 31, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34
March 31, 2023	EX-10.12	Fourth Amendment to Loan and Security Agreement dated as of December 7, 2022, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender Certain information in this document has been omitted pursuant to Regulation S-K, Item 601(b)(10).
March 31, 2023	EX-99.5	JOINT FILING AGREEMENT Exhibit 99.5 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Alimera Sciences, Inc., a Delaware corporation. This Jo
March 28, 2023	SC 13D/A	ALIM / Alimera Sciences Inc. / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) Da
March 27, 2023	EX-3.1	Certificate of Designation of Series B Convertible Preferred Stock EX-3.1 2 alim-20230323xex31.htm EX-3.1 Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Pursuant to Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing
March 27, 2023	EX-10.1	Securities Purchase Agreement, dated March 24, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as may be amended or restated, this “Agreement”) is dated as of March 24, 2023, between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”, and collectively, the “Purchasers”). WHEREAS, sub
March 27, 2023	EX-4.1	Form of Warrant to Purchase Shares of Common Stock EX-4.1 5 alim-20230323xex41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD
March 27, 2023	EX-4.1	Form of Warrant to Purchase Shares of Common Stock EX-4.1 5 alim-20230323xex41.htm EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD
March 27, 2023	EX-3.3	Certificate of Elimination of Series C Convertible Preferred Stock (filed as Exhibit 3.3 to the Registrant’s Form 8-K, as filed March 27, 2023, and incorporated herein by reference) Exhibit 3.3 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows: FIRST: By a Certificate of Designation filed with the
March 27, 2023	EX-10.1	Securities Purchase Agreement, dated March 24, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as may be amended or restated, this “Agreement”) is dated as of March 24, 2023, between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser”, and collectively, the “Purchasers”). WHEREAS, sub
March 27, 2023	EX-3.2	Certificate of Elimination of Series A Convertible Preferred Stock Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows: FIRST: By a Certificate of Designation filed with the
March 27, 2023	EX-99.1	Press Release of Alimera Sciences, Inc. dated March 27, 2023 Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility · Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000 · Completes $12 million private placement of preferred stock and warrants with conversion price and exercise price at 55% premium to the closing share
March 27, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
March 27, 2023	EX-3.1	Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, as filed on March 27, 2023, and incorporated herein by reference). EX-3.1 2 alim-20230323xex31.htm EX-3.1 Exhibit 3.1 ALIMERA SCIENCES, INC. CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Pursuant to Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Alimera Sciences, Inc. (the “Corporation”), a corporation organized and existing
March 27, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (
March 27, 2023	EX-99.1	Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility EX-99.1 8 alim-20230323xex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility · Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000 · Completes $12 million private placement of preferred stock and warrants with conversion price and exercise
March 27, 2023	EX-10.2	Registration Rights Agreement, dated March 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto (filed as Exhibit 10.2 to the Registrant’s Form 8-K, as filed on March 27, 2023, and incorporated herein by reference) Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 24, 2023, by and among Alimera Sciences, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing Date (as defined below)
March 27, 2023	EX-3.2	Certificate of Elimination of Series A Convertible Preferred Stock (filed as Exhibit 3.2 to the Registrant’s Form 8-K, as filed March 27, 2023, and incorporated herein by reference) Exhibit 3.2 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows: FIRST: By a Certificate of Designation filed with the
March 27, 2023	EX-10.2	Registration Rights Agreement, dated March 24, 2023, by and among Alimera Sciences, Inc. and the purchasers party thereto Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 24, 2023, by and among Alimera Sciences, Inc., a Delaware corporation (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing Date (as defined below)
March 27, 2023	EX-3.3	Certificate of Elimination of Series C Convertible Preferred Stock Exhibit 3.3 CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151(g) of the Delaware General Corporation Law Alimera Sciences, Inc. (the “Company”), a corporation organized and existing under the laws of the State of Delaware, certifies as follows: FIRST: By a Certificate of Designation filed with the
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
March 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2023 ALIMERA SCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
March 1, 2023	EX-99.1	Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors ATLANTA (February 27, 2023) – Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhne
January 10, 2023	EX-99.1	Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer EX-99.1 3 alim-20230106xex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer ATLANTA, January 9, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maint
January 10, 2023	EX-10.1	Employment Agreement, dated as of January 9, 2023, by and between Alimera Sciences, Inc. and Russell L. Skibsted (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed January 10, 2023, and incorporated herein by reference) Exhibit 10.1 EMPLOYMENT AGREEMENT WITH ALIMERA SCIENCES, INC. This Employment Agreement (this “Agreement”) is entered into between Alimera Sciences, Inc., a Delaware corporation (the “Company”), and Russell L. Skibsted (“Executive”), as of January 9, 2022 (the “Effective Date”). RECITALS: WHEREAS, the Company is engaged in the business of developing, marketing and selling ophthalmic pharma
January 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 ALIMERA SCIENCES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2023 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
December 8, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
December 8, 2022	EX-99.1	Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement ? ? ATLANTA, December 8, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (?Alimera?), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer
November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 o TRANSITION REPO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 14, 2022	EX-99.1	Alimera Sciences Announces Third Quarter 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Announces Third Quarter 2022 Financial Results · Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 o Net Product Revenue Was Unfavorably Impacted by Approximately $800,000 in Foreign Currency Fluctuations · Excluding Fluctuations in Foreign Currency Exchange Rates, Consolidated Net Product Revenue Would Hav
November 14, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 ALIMERA SCIENCE UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 10, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
November 4, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 o TRANSITION REPORT PU Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
July 27, 2022	EX-99.1	Alimera Sciences Announces Second Quarter 2022 Financial Results Exhibit 99.1 ? FOR IMMEDIATE RELEASE ? Alimera Sciences Announces Second Quarter 2022 Financial Results ? ? Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021 ? U.S. End User Demand up 45% vs. Second Quarter of 2021 ? International Segment End User Demand Up 21% vs. Second Quarter of 2021 ? ? ATLANTA, July 27, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera),
July 27, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi
July 13, 2022	8-K	Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi
June 7, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fil
June 7, 2022	EX-99.1	Corporate Presentation Exhibit 99.1
June 1, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy
June 1, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy
May 25, 2022	SC 13D	ALIM / Alimera Sciences Inc / Caligan Partners LP - ALIMERA SCIENCES, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) David
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 o TRANSITION REPORT P Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 12, 2022	EX-10.11.G	Third Amendment to Loan and Security Agreement dated as of February 22, 2022, by and among Alimera Sciences, Inc., SLR Investment Corp, as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender (filed as Exhibit 10.11.G to the Registrant’s Quarterly Report on Form 10-Q, as filed May 12, 2022, and incorporated herein by reference) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
May 9, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission File
May 9, 2022	EX-99.1	Alimera Sciences Reports First Quarter 2022 Results Exhibit 99.1 ? ? ? ? FOR IMMEDIATE RELEASE ? Alimera Sciences Reports First Quarter 2022 Results ? ? Consolidated Net Revenue of $11.9 Million Up 6% vs. First Quarter of 2021 ? U.S. Net Revenue Increased 23% vs. First Quarter of 2021 ? U.S. End User Demand Up 25% vs. First Quarter of 2021 ? ? ATLANTA, May 9, 2022 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company wh
April 29, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission
March 23, 2022	EX-21.1	List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business) Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries ? ? Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences B.V. The Netherlands Alimera Sciences B.V. Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe L
March 23, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34
March 23, 2022	EX-4.2	Description of Securities (filed as Exhibit 4.2 to the Registrant’s Form 10-K, as filed March 23, 2022, and incorporated herein by reference) Exhibit 4.2 DESCRIPTION OF SECURITIES ? Unless the context otherwise requires, throughout this exhibit, the words ?we,? ?us,? or ?our? refer to Alimera Sciences, Inc. and its subsidiaries (as applicable). ? Common Stock ? We currently have authorized 150,000,000 shares of common stock, par value $0.01 per share. As of March 1, 2022, there were 6,992,654 shares of our common stock issued and outsta
March 23, 2022	S-8	As filed with the Securities and Exchange Commission on March 23, 2022 As filed with the Securities and Exchange Commission on March 23, 2022 Registration No.
March 23, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107.1 Calculation of Filing Fee Tables ? FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ? ALIMERA SCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) ? Table 1: Newly Registered Securities ? ? ? Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amou
February 28, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
February 24, 2022	EX-99.1	Alimera Sciences Reports Fourth Quarter and FY 2021 Results Exhibit 99.1 ? ? ? ? ? ? Alimera Sciences Reports Fourth Quarter and FY 2021 Results ? Fourth Quarter Highlights: ? Consolidated Net Revenue of $14 Million Up 15% vs. Third Quarter of 2021; Up 1% vs. Fourth Quarter of 2020 ? Full Year 2021 Highlights: ? Consolidated Net Revenue of $59 Million Up 16% vs 2020 ? Consolidated Net Product Revenue of $48 Million ? U.S. Net Revenue Increased 8% vs. 2020
February 24, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2022 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
February 3, 2022	SC 13G/A	ALIM / Alimera Sciences Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment No. 3 Under the Securities Exchange Act of 1934 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259103 (CUSIP Number) February 2, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
December 1, 2021	EX-99.1	Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors Exhibit 99.1 ? ? ? Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directors ? ATLANTA (December 1, 2021) ? Alimera Sciences, Inc. (Nasdaq: ALIM) (?Alimera?), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of
December 1, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
November 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 o TRANSITION REPO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 5, 2021	EX-10.7.H	Change in Control Severance Agreement between Alimera Sciences, Inc., and Philip J. Ashman, Ph.D. as of July 16, 2021 (filed as Exhibit 10.7.H to the Registrant’s Quarterly Report on Form 10-Q, as filed November 5, 2021 and incorporated herein by reference) Exhibit 10.7H CHANGE IN CONTROL SEVERANCE AGREEMENT BETWEEN PHILIP J. ASHMAN, PH.D. AND ALIMERA SCIENCES, INC. ? This Change in Control Severance Agreement (this ?Agreement?) is entered into between Alimera Sciences, Inc., a Delaware corporation (together with its subsidiaries, the ?Company?), and Philip J. Ashman, Ph.D. (?Executive?), as of July 16, 2021 (the ?Effective Date?). ? RECITALS: ? WHER
October 29, 2021	EX-99.5	UK Sub-Plan to the Alimera Sciences, Inc. 2019 Omnibus Incentive Plan (filed as Exhibit 99.5 to the Registrant’s Registration Statement on Form S-8, as filed on October 29, 2021 and incorporated herein by reference) Exhibit 99.5 Neither this document, nor any stock option agreement connected with it, is an approved prospectus for the purposes of section 85(1) of the Financial Services and Markets Act 2000 (?FSMA?) and no offer of transferable securities to the public (for the purposes of section 102B of FSMA) is being made in connection with the UK Sub-Plan to the Alimera Sciences, Inc. 2019 Omnibus Incentive
October 29, 2021	S-8	As filed with the Securities and Exchange Commission on October 29, 2021 As filed with the Securities and Exchange Commission on October 29, 2021 Registration No.
October 29, 2021	EX-99.6	Form of UK Sub-Plan Stock Option Agreement (filed as Exhibit 99.6 to the Registrant’s Registration Statement on Form S-8, as filed on October 29, 2021 and incorporated herein by reference) Exhibit 99.6 UK SUB-PLAN TO THE ALIMERA SCIENCES, INC. 2019 OMNIBUS INCENTIVE PLAN STOCK OPTION AGREEMENT ? THIS STOCK OPTION AGREEMENT (the ?Agreement?) is made and entered into as of the date set forth on Schedule I (?Schedule I?) attached hereto (the ?Date of Grant?) by and between Alimera Sciences, Inc., a Delaware corporation (the ?Company?), and the employee named on Schedule I (the ?Partici
October 28, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
October 28, 2021	EX-99.1	Alimera Sciences Announces Third Quarter 2021 Financial Results Exhibit 99.1 ? ? ? FOR IMMEDIATE RELEASE ? Alimera Sciences Announces Third Quarter 2021 Financial Results ? ? Consolidated Net Revenue of $12.2 Million Down 2% vs. Third Quarter of 2020 and Up 14% vs. Second Quarter of 2021 ? U.S. End User Demand up 15% vs. Third Quarter of 2020 and Second Quarter of 2021 ? ATLANTA, October 28, 2021 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global phar
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 o TRANSITION REPORT PU Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 13, 2021	EX-99.1	Alimera Sciences Announces Second Quarter 2021 Financial Results Exhibit 99.1 ? ? ? ? ? FOR IMMEDIATE RELEASE Alimera Sciences Announces Second Quarter 2021 Financial Results ? ? Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020 ? Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020 ? Net Income of $7.6 Million vs. Net Loss of $2.5 Million in Second Quarter of 2020 ? End User Demand up 16% on a Same Count
August 13, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission
June 16, 2021	EX-10.1	Alimera Sciences, Inc. 2019 Omnibus Incentive Plan, as amended pursuant to stockholder approval on June 15, 2021 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, as filed on June 16, 2021, and incorporated herein by reference) Exhibit 10.1 ? ALIMERA SCIENCES, INC. ? 2019 OMNIBUS INCENTIVE PLAN ? As Amended Pursuant to Stockholder Approval on June 15, 2021 ? ? ARTICLE I ? PURPOSE ? Alimera Sciences, Inc. (the ?Company?) has established the Alimera Sciences, Inc. 2019 Omnibus Incentive Plan (the ?Plan?) to attract, retain and motivate directors, officers, employees and consultants of the Company and its Subsidiaries who a
June 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission Fi
June 1, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
May 7, 2021	EX-10.14.F	Second Amendment to Loan and Security Agreement dated as of March 30, 2021, by and among Alimera Sciences, Inc., SLR Investment Corp. (f/k/a Solar Capital Ltd.), as Collateral Agent, and the parties signatory thereto as Lenders, including SLR in its capacity as a Lender (filed as Exhibit 10.14.F to the Registrant’s Quarterly Report on Form 10-Q, as filed May 7, 2021, and incorporated herein by reference) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
May 7, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
April 30, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Alimera Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 016259202 (CUSIP Number) April 16, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
April 30, 2021	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Proxy
April 30, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive Pro
April 28, 2021	EX-99.1	Alimera Sciences Announces First Quarter 2021 Financial Results Exhibit 99.1 ? ? ? ? ? FOR IMMEDIATE RELEASE Alimera Sciences Announces First Quarter 2021 Financial Results ? ? ATLANTA, April 28, 2021 - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for th
April 28, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
April 14, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
April 14, 2021	EX-10.3	Warrant Subscription Agreement by and between Alimera Sciences, Inc. and Ocumension Therapeutics, dated as of April 14, 2021 (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference) Exhibit 10.3 Dated 14 April 2021 ? ? ? ? ? OCUMENSION THERAPEUTICS (as Issuer) ? ? and ? ? ALIMERA SCIENCES, INC. (as Subscriber) ? ? ? ? ? WARRANT SUBSCRIPTION AGREEMENT ? ? ? ? ? THIS AGREEMENT is dated 14 April 2021 ? BETWEEN: ? (1)OCUMENSION THERAPEUTICS (??????), a company incorporated under the laws of the Cayman Islands with limited liability having its registered office at P.O. Box 31119 G
April 14, 2021	EX-99.1	Alimera Sciences receives $20 million from Ocumension Therapeutics Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences receives $20 million from Ocumension Therapeutics · Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone payments · Ocumension makes a $10 million equity investment in Alimera ATLANTA, April 14, 2021 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera
April 14, 2021	EX-10.4	Exclusive License Agreement by and between and Ocumension (Hong Kong) Limited, dated as of April 14, 2021 (filed as Exhibit 10.4 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
April 14, 2021	EX-10.2	Voting and Investor Rights Agreement by and between Alimera Sciences, Inc. and Ocumension Therapeutics, dated as of April 14, 2021 (filed as Exhibit 10.2 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
April 14, 2021	EX-10.1	Share Purchase Agreement by and between Ocumension Therapeutics and Alimera Sciences, Inc., dated as of April 14, 2021 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K as filed on April 14, 2021 and incorporated herein by reference) Exhibit 10.1 Execution Version SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this ?Agreement?) is made as of April 14, 2021, by and between Ocumension Therapeutics, incorporated in the Cayman Islands with limited liability (?Investor?), and Alimera Sciences, Inc., a Delaware corporation (the ?Company?). WHEREAS, pursuant to the terms and subject to the conditions set forth in this Agreem
March 30, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commission F
March 5, 2021	EX-4.3	Description of Securities Exhibit 4.3 DESCRIPTION OF SECURITIES ? Unless the context otherwise requires, throughout this exhibit, the words ?we,? ?us,? or ?our? refer to Alimera Sciences, Inc. and its subsidiaries (as applicable). ? Common Stock ? We currently have authorized 150,000,000 shares of common stock, par value $0.01 per share. As of March 1, 2021, there were 5,753,434 shares of the registrant?s common stock issu
March 5, 2021	EX-21.1	List of subsidiaries of the Registrant (including jurisdiction of organization and names under which subsidiaries do business) Exhibit 21.1 Alimera Sciences, Inc. List of Subsidiaries ? ? Name of Wholly-Owned Subsidiary Jurisdiction of Organization Name under which the subsidiary conducts business Alimera Sciences Limited United Kingdom Alimera Sciences Limited Alimera Sciences B.V. The Netherlands Alimera Sciences B.V. Alimera Sciences Opthamologie GmbH Germany Alimera Sciences Opthamologie GmbH Alimera Sciences Europe L
March 5, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34
February 24, 2021	EX-99.1	Alimera Sciences Reports Fourth Quarter and 2020 Results Exhibit 99.1 ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE ? Alimera Sciences Reports Fourth Quarter and 2020 Results ? Fourth Quarter Highlights: ? Consolidated Net Revenue of $13.8 Million Up 10% vs. Third Quarter of 2020 ? Consolidated Net Revenue Down 20% vs. Fourth Quarter of 2019 Due to COVID-19 Impact ? Net Loss of $(1.0) Million vs. Net Income of $0.5 Million in Fourth Quarter of 2019 ? $1.1 Million
February 24, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio
February 19, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2021 ALIMERA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-34703 20-0028718 (State or other Jurisdiction of Incorporation) (Commissio

ALIM / Alimera Sciences, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)